Cellectar Biosciences has teamed with Avicenna Oncology GmbH, a precision medicine company based in Basel, Switzerland.
The companies will combine their technologies to fight solid-tumor cancers.
Cellectar is creating a targeted delivery method for cancer drugs. Avicenna Oncology combines both precision medicine and drug conjugates against resistant cancers.
